Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM
← catalyst calendarSponsored by NovoCure Ltd. (industry) · NVCR — their whole pipeline →.
Phase
Not applicable
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
981actual
Sites
133
Countries
Austria, Belgium, Canada +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-12-08 | actual | When the study began enrolling |
| Primary completion | 2026-02-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-19 | actual | The whole study's end, after follow-up |
| First posted | 2020-07-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Glioblastoma Multiforme
Intervention
- Device: Optune®
Primary outcome
what the primary-completion date above is the date OFOverall Survival (OS)
measured 5 years
Publications
- PMID 36336899 — linked by the registry
- PMID 35574391 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · NVCR's whole pipeline · Catalyst calendar · Every registered study · What changed